研究单位：[1]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[2]Hebei four Hospital Shijiazhuang, Hebei, China[3]The First Affiliated Hospital of Xinxiang Medical College Xinxiang, Henan, China[4]The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China[5]Tongji Hospital, Tongji Medical College Wuhan, Hubei, China
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome.
The purpose of this study is to evaluate the progression free survival and safety of irinotecan plus S1 versus S1 alone in the patients with previously treated advanced esophageal cancer
